14 Best Low Risk High Growth Stocks to Buy Right Now

7. Novartis AG (NYSE:NVS)

Following the successful spin-off of its Sandoz generics division in late 2023, Novartis AG (NYSE:NVS) has transformed into a high-margin, pure-play innovative medicines company that is currently outpacing its peers in both pipeline velocity and capital efficiency. In early 2026, Novartis reported that its core growth drivers, Kisqali (breast cancer), Kesimpta (multiple sclerosis), and Pluvicto (radioligand therapy), were seeing explosive growth. Specifically, Kisqali sales surged by 57% and Pluvicto by 42% in constant currencies, providing the high-growth kicker that elite investors look for. The firm has built a massive competitive moat in radioligand therapy. With the FDA-approved Millburn facility scaling up in early 2026, the company is effectively the leader of this high-margin cancer treatment niche.

READ ALSO: D. E. Shaw Stock Portfolio: Top 10 Stocks to Buy.

Novartis AG (NYSE:NVS) stock offers utility-like safety combined with tech-like margins. The company achieved a 40.1% core operating margin in 2025/2026, an elite figure that provides a massive buffer against inflationary pressures and R&D costs. It generated $17.6 billion in free cash flow last year. This liquidity allows it to fund mid-sized bolt-on acquisitions, like the $2 billion Excellergy deal in March 2026, without stressing its balance sheet or taking on dangerous debt. Novartis is a premier income sanctuary. In early 2026, it proposed a dividend of CHF 3.70 per share, a 5.7% increase, yielding approximately 3%. It has a decades-long track record of uninterrupted payouts, providing a reliable paycheck for patient holders.